PL363391A1 - Pochodne ftaloazynono-piperydynowe jako inhibitory PDE4 - Google Patents

Pochodne ftaloazynono-piperydynowe jako inhibitory PDE4

Info

Publication number
PL363391A1
PL363391A1 PL02363391A PL36339102A PL363391A1 PL 363391 A1 PL363391 A1 PL 363391A1 PL 02363391 A PL02363391 A PL 02363391A PL 36339102 A PL36339102 A PL 36339102A PL 363391 A1 PL363391 A1 PL 363391A1
Authority
PL
Poland
Prior art keywords
phthalayinone
piperidino
derivatives
pde4 inhibitors
pde4
Prior art date
Application number
PL02363391A
Other languages
English (en)
Inventor
Gerhard Grundler
Beate Schmidt
Geert Jan Sterk
Armin Hatzelmann
Daniela Bundschuh
Hans-Peter Kley
Hendrik Timmerman
Johannes A.M. Christiaans
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL363391A1 publication Critical patent/PL363391A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
PL02363391A 2001-02-15 2002-02-14 Pochodne ftaloazynono-piperydynowe jako inhibitory PDE4 PL363391A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01103496 2001-02-15
PCT/EP2002/001547 WO2002064584A1 (en) 2001-02-15 2002-02-14 Phthalayinone-piperidino-derivatives as pde4 inhibitors

Publications (1)

Publication Number Publication Date
PL363391A1 true PL363391A1 (pl) 2004-11-15

Family

ID=8176497

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363391A PL363391A1 (pl) 2001-02-15 2002-02-14 Pochodne ftaloazynono-piperydynowe jako inhibitory PDE4

Country Status (22)

Country Link
US (3) US6953853B2 (pl)
EP (1) EP1362044A1 (pl)
JP (1) JP4301812B2 (pl)
KR (1) KR20030074817A (pl)
CN (1) CN1524080A (pl)
AU (1) AU2002234634B2 (pl)
BG (1) BG108124A (pl)
BR (1) BR0207278A (pl)
CA (1) CA2438520C (pl)
CZ (1) CZ20032491A3 (pl)
EA (1) EA200300836A1 (pl)
EE (1) EE05386B1 (pl)
HR (1) HRP20030636B1 (pl)
HU (1) HUP0303193A3 (pl)
IL (1) IL156812A0 (pl)
MX (1) MXPA03007310A (pl)
NO (1) NO325245B1 (pl)
NZ (1) NZ527424A (pl)
PL (1) PL363391A1 (pl)
SK (1) SK11382003A3 (pl)
WO (1) WO2002064584A1 (pl)
ZA (1) ZA200306815B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527424A (en) 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
HRP20050198A2 (hr) * 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
US20060167001A1 (en) * 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
US20060166995A1 (en) * 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
PL378247A1 (pl) * 2003-01-14 2006-03-20 Altana Pharma Ag Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
WO2004098633A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde-4 inhibitor and a tnf alpha antagonist
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098605A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Pharmaceutical composition comprising a pde4 inhibitor and il-1 trap
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
EP1716133B1 (en) 2004-02-04 2008-03-26 Nycomed GmbH 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
EP1720854A1 (en) * 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
CN102600144A (zh) 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
JP2009523805A (ja) * 2006-01-17 2009-06-25 シグナル ファーマシューティカルズ，エルエルシー ＴＮＦα、ＰＤＥ４及びＢ−ＲＡＦの阻害剤、それらの組成物及びそれらの使用法
PT2359826E (pt) 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
CN101657441B (zh) 2007-05-16 2013-09-11 塔科达有限责任公司 作为pde4抑制剂的吡唑啉酮衍生物
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
MX2013014888A (es) 2011-06-17 2014-02-27 Takeda Gmbh Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida.
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
JP6820717B2 (ja) 2016-10-28 2021-01-27 株式会社日立ハイテク プラズマ処理装置
CN113121417A (zh) * 2019-12-30 2021-07-16 苏州盛迪亚生物医药有限公司 一种新型哌啶衍生物及其药物用途
WO2021192210A1 (ja) 2020-03-27 2021-09-30 株式会社日立ハイテク 半導体製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3245165B2 (ja) * 1991-10-09 2002-01-07 シンテックス（ユー・エス・エイ）・インコーポレイテッド ピリドピリダジノンおよびピリダジンチオン化合物
DK0672031T3 (da) 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
SK283270B6 (sk) * 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
US6380196B1 (en) * 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
WO2001019818A1 (en) 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
AU781137B2 (en) * 1999-10-25 2005-05-05 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
ATE374189T1 (de) * 1999-10-25 2007-10-15 Nycomed Gmbh Phthalazinon-derivate als pde 4 hemmer
CN1471515A (zh) 2000-06-05 2004-01-28 ��̹��ҽҩ��˾ 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
NZ527424A (en) 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
BR0209076A (pt) 2001-04-25 2004-08-10 Altana Pharma Ag Derivados de piperazino e seu uso como inibidor de pde4
EP1385848A2 (en) 2001-04-25 2004-02-04 ALTANA Pharma AG Phtalazinones derivatives useful as pde4/7 inhibitors
HRP20050198A2 (hr) 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
US20060166995A1 (en) 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives

Also Published As

Publication number Publication date
WO2002064584A1 (en) 2002-08-22
BG108124A (bg) 2004-08-31
EE05386B1 (et) 2011-02-15
ZA200306815B (en) 2004-06-17
NO325245B1 (no) 2008-03-10
CA2438520A1 (en) 2002-08-22
CA2438520C (en) 2011-10-04
IL156812A0 (en) 2004-02-08
CN1524080A (zh) 2004-08-25
US6953853B2 (en) 2005-10-11
MXPA03007310A (es) 2003-12-04
EA200300836A1 (ru) 2004-02-26
BR0207278A (pt) 2004-02-10
US20070129373A1 (en) 2007-06-07
HUP0303193A2 (hu) 2003-12-29
SK11382003A3 (sk) 2004-01-08
NO20033618D0 (no) 2003-08-14
KR20030074817A (ko) 2003-09-19
US7531540B2 (en) 2009-05-12
HUP0303193A3 (en) 2007-08-28
HRP20030636A2 (en) 2005-06-30
AU2002234634B2 (en) 2007-07-26
NZ527424A (en) 2005-02-25
US20040067946A1 (en) 2004-04-08
HRP20030636B1 (en) 2012-05-31
US7179810B2 (en) 2007-02-20
NO20033618L (no) 2003-10-15
JP4301812B2 (ja) 2009-07-22
CZ20032491A3 (cs) 2004-01-14
EE200300311A (et) 2003-10-15
EP1362044A1 (en) 2003-11-19
JP2004518727A (ja) 2004-06-24
US20050234062A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
PL373146A1 (pl) Pochodne pirydazynonu jako inhibitory PDE4
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
IL160213A0 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
AU2003255376A1 (en) Piperidine-derivatives as pde4 inhibitors
PL370909A1 (pl) Cis-imidazoliny jako inhibitory MDM2
HUP0401052A3 (en) Dna-pk inhibitors
SI1671949T1 (sl) Substituirani pridinilamini
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
PL362643A1 (pl) Podstawione fluoroalkoksyfenylosulfonylomoczniki
GB2385939B (en) Combination square
AU2002304853A1 (en) Substituted benzopyranones as telomerase inhibitors
PT1406858E (pt) 4-aminociclo-hexanóis substituídos
PL363544A1 (pl) Nowe pochodne piperazynowe
HUP0303185A3 (en) Glyt-1 inhibitors
PL364601A1 (pl) Podstawione związki benzoheterocykliczne zawierające azot
GB0109278D0 (en) Enzyme inhibitors
HK1060560A (en) Phthalazinone-piperidino-derivatives as pde4 inhibitors
GB2373763B (en) Sledge
SI1272488T1 (sl) Tri-aril-substituirani-etan PDE4-inhibitorji
GB0101135D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors
GB2405093B (en) DNA-PK inhibitors
AU2002254693A1 (en) Heterocyclyldicarbamides as caspase inhibitors
HK1063313A (en) Heterocyclyldicarbamides as caspase inhibitors

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)